All In Biotech

Drug Trial Radar · NCT03989310

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

A Phase I/II, Open-label, One-arm, Single-center Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Local Advanced/Metastatic Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Dec 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 1, 2019

Primary completion

May 31, 2021

Study completion Mar 31, 2022

Sponsor

Lead sponsor
Chinese PLA General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The outcome of pancreatic cancer is extremely poor. NCCN guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen, but the response rate is unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This one-arm, phase I/II study is designed to assess the safety and efficacy of Manganese primed combined therapy of anti-PD-1 antibody and chemotherapy.

Conditions

  • Pancreatic Cancer

Interventions

  • Manganese ChlorideDrug

    Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle

  • nab-paclitaxelDrug

    Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle

  • GemcitabineDrug

    Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle

  • anti-PD-1 antibodyDrug

    Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects with treatment-related adverse events (AEs)Time frame: 12 months
  2. Disease control rate (DCR)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Biotherapeutic Department of Chinese PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.